Polaris Rx

Provides pharmacy dispensing, clinical, logistics, regulatory, and technology services for complex-care populations.

Website: https://polarisrx.com/

Cover Block

From the public record

Field Value
Name Polaris Rx
Tagline Provides pharmacy dispensing, clinical, logistics, regulatory, and technology services for complex-care populations. [Polaris Rx]
Headquarters Fort Lauderdale, US [Polaris Rx]
Founded 2015 [Polaris Rx]
Stage Other
Business model B2B
Industry Healthtech
Technology Software (Non-AI)
Geography North America
Growth profile SMB / Main Street
Funding label Undisclosed

Links

From the public record

The Short Version

PUBLIC Polaris Rx provides pharmacy dispensing alongside clinical, logistics, regulatory, and software-enabled workflow services for complex-care populations, and it merits attention now because large pharmaceutical partners have recently entrusted it with named dispensing and distribution roles in specialty and at-home vaccination programs [Polaris Rx, April 2025] [Business Wire, November 2026]. Founded in 2015, the company presents itself as an independently owned operator serving long-term care, post-acute, correctional, PACE, and specialty pharmacy settings from a Fort Lauderdale base, with public materials also describing a footprint of more than 20 pharmacies nationwide, though that operating scale is sourced to company materials rather than independent reporting [Polaris Rx] [Polaris Rx, Unknown].

The offering is broader than a single dispensing function: Polaris pairs fulfillment with clinical support, logistics, regulatory services, and customer-facing software such as PolarisConnect for order tracking, invoices, and reporting, plus PolarisDirect for HIPAA-compliant messaging and file sharing [Polaris Rx, Unknown] [Microsoft AppSource]. That combination appears to be the practical differentiation. The software is positioned as workflow infrastructure around pharmacy operations rather than a standalone SaaS product, which may matter for retention if institutional customers prefer an integrated service relationship over point solutions [Polaris Rx, Unknown].

Leadership is only partially visible in public sources, which is itself relevant. Yasuhiro Endo is identified as CEO in available materials, while Todd Zisek is presented by the company as an operations leader with more than 20 years of long-term care pharmacy experience, and Joseph Mauro and Steve Baker are tied to specialty operations and operating leadership respectively across company and profile sources [Polaris Rx, Unknown] [LinkedIn, Retrieved 2026] [RocketReach, Retrieved 2026].

On funding, the public record is thin. The company is privately held and independently owned according to its own materials, but no disclosed financing rounds, named investors, or accelerators were confirmed in the retrieved sources, which pushes the underwriting question away from venture signaling and toward operating quality, partner durability, and customer concentration risk [Polaris Rx] [Craft.co]. The business model is plainly B2B, centered on institutional pharmacy services and pharmaceutical-partner programs rather than consumer acquisition [Polaris Rx, Unknown].

Over the next 12 to 18 months, the key public indicators to watch are whether the Bristol Myers Squibb ZENBEXUS dispensing role translates into a repeatable specialty-pharma channel position, whether the FluMist Home relationship continues across additional seasons, and whether Polaris shows evidence of expanding its software layer from portal utility into deeper workflow dependence [Business Wire, November 2026] [Polaris Rx, April 2025] [AOL, September 2026]. For now, the company reads as an operating platform with credible partner validation but limited financial transparency, which makes execution evidence more important than narrative.

Unconfirmed -- This section relies materially on company materials, with partial corroboration from Business Wire, LinkedIn, RocketReach, and Microsoft AppSource.

Taxonomy Snapshot

Axis Value
Stage Other
Business Model B2B
Industry / Vertical Healthtech
Technology Type Software (Non-AI)
Geography North America
Growth Profile SMB / Main Street
Funding Undisclosed

The Company in Brief

PUBLIC

Polaris Rx presents less like a venture-backed software company and more like an operating platform built around pharmacy infrastructure. The public record supports a 2015 founding date and places the business in Fort Lauderdale, Florida, where its contact page lists 2900 NW 60th Street as the company address [Polaris Rx] [Polaris Rx, Unknown]. On its website, the company describes its scope in plain terms: pharmacy dispensing plus clinical, logistics, regulatory, and technology services for long-term, post-acute, correctional, PACE, and specialty pharmacy populations [Polaris Rx, Unknown] [Polaris Rx, Unknown].

The milestone trail that is publicly visible is operational rather than financial. In April 2025, Polaris said it had been named exclusive U.S. distributor for AstraZeneca's FluMist Home service for the 2025 to 2026 flu season, and that dispensing and shipping would begin from five pharmacy locations with Asembia and ASPN Pharmacies involved in the deployment stack [Polaris Rx, April 2025]. In November 2026, Business Wire reported that Bristol Myers Squibb selected Polaris Rx to dispense ZENBEXUS, which the announcement described as the first FDA-approved CELMoD therapy for multiple myeloma [Business Wire, November 2026]. Those two announcements do not establish revenue scale, but they do indicate that large pharmaceutical partners are willing to route branded distribution work through Polaris's network [Polaris Rx, April 2025] [Business Wire, November 2026].

Founder identity, legal entity detail, and capital formation are not established in the cited public sources used for this section. What is clear from the company website is that Polaris frames itself as an independently owned pharmacy-services operator serving multiple regulated care settings from a Florida base, with national ambitions visible through manufacturer partnerships and multi-site dispensing activity [Polaris Rx, Unknown] [Polaris Rx, April 2025].

Unconfirmed -- This section relies primarily on company website disclosures, with one milestone corroborated by Business Wire.

What They Have Built

MIXED

What stands out first is that Polaris Rx presents as an operating pharmacy platform with software wrapped around service delivery, not as a standalone SaaS vendor. Public materials describe the company as providing pharmacy dispensing plus clinical, logistics, regulatory, and technology services for complex-care populations across long-term, post-acute, correctional, PACE, and specialty settings [Polaris Rx] [Polaris Rx About Us]. That matters because the product surface appears to be embedded in regulated workflows, where compliance, fulfillment, and care coordination are part of the offering rather than adjacent features [Polaris Rx] [Polaris Rx About Us].

The clearest software component in public view is PolarisConnect, which the company describes as a customer portal for medication workflows, order tracking, invoices, reporting, and related account tools, with login-gated access suggesting it is an active operating interface rather than a marketing placeholder [Polaris Rx] [PolarisConnect]. Separately, PolarisDirect is presented as a secure communications layer for pharmacy customers, with HIPAA-compliant messaging and file sharing, verification, alerts, notifications, timestamps, and read receipts available across devices [PolarisDirect, Retrieved 2026] [Microsoft AppSource]. Public evidence supports the existence and function of these tools, but not the underlying stack, integration depth, or adoption levels, so any claim beyond workflow support would run ahead of the record.

Product evidence from press coverage also shows Polaris participating in manufacturer-linked distribution programs, which says more about operational capability than software novelty. In April 2025, the company said it began dispensing and shipping FluMist Home from five pharmacy locations as part of AstraZeneca's 2025 to 2026 season rollout, alongside Asembia and ASPN Pharmacies [Polaris Rx, April 2025]. In November 2026, Business Wire reported that Bristol Myers Squibb selected Polaris Rx to dispense ZENBEXUS, the first FDA-approved CELMoD therapy for multiple myeloma, tying Polaris into a higher-acuity specialty workflow where payer, regulatory, and patient-support coordination typically matter as much as the script itself [Business Wire, November 2026].

Unconfirmed -- This section relies heavily on company website and company announcement materials, with limited independent corroboration from Microsoft AppSource and Business Wire.

Market Size and Demand

PUBLIC

The market matters now because Polaris Rx sits at the intersection of pharmacy fulfillment, specialty drug distribution, and institutionally managed care, where regulation and drug complexity are pushing more volume toward operators that can combine dispensing with workflow, compliance, and care coordination [Polaris Rx] [Business Wire, November 2026].

The limiting factor in sizing this market is evidence quality rather than category breadth. No cited third-party market report in the available record provides a direct TAM, SAM, or SOM for Polaris Rx’s combined footprint across long-term care, post-acute, correctional, PACE, infusion, and specialty pharmacy, so any sizing exercise here has to be framed as adjacent-market analysis rather than a precise company market map [Polaris Rx] [Craft.co]. What is verifiable from public materials is the breadth of the service envelope Polaris claims to cover: long-term care, post-acute, correctional, PACE, and specialty pharmacy on the corporate site, plus a specific dispensing role in a newly approved multiple myeloma therapy through Bristol Myers Squibb [Polaris Rx] [Business Wire, November 2026]. That mix suggests exposure to multiple healthcare spend pools rather than a single narrow software budget.

Demand drivers are easier to observe than market size. The company’s public materials repeatedly emphasize complex-care populations and settings where medication fulfillment is entangled with logistics, clinical oversight, and regulatory execution, including long-term care and correctional health programs tied to Medicaid Section 1115 waiver implementation and pre-release coverage [Polaris Rx]. The April 2025 FluMist Home announcement adds a second tailwind: drug makers appear willing to route specialized at-home distribution programs through pharmacy partners that can coordinate dispensing, shipping, and supporting infrastructure across several sites, even when other parties supply hub services or technology layers [Polaris Rx, April 2025].

A related tailwind comes from specialty pharma commercialization itself. Polaris Rx’s November 2026 selection by Bristol Myers Squibb to dispense ZENBEXUS links the company to a therapy launch in hematology, a segment where manufacturers often rely on limited or tightly managed dispensing networks to support access, reimbursement, adherence, and compliance workflows [Business Wire, November 2026]. That does not establish market share, but it does indicate that the relevant opportunity extends beyond commodity prescription volume and into manufacturer-directed channel relationships.

Adjacent and substitute markets matter because Polaris Rx is not selling into one clean category. Its portal and secure messaging tools place part of the offering near pharmacy workflow software and provider communications infrastructure, while its core operations overlap with long-term care pharmacy, specialty pharmacy services, institutional dispensing, and correctional healthcare support [Polaris Rx] [Microsoft AppSource]. In practice, buyers could address pieces of the problem through separate software vendors, local pharmacy operators, specialty distributors, or integrated care partners, which means Polaris Rx’s addressable opportunity likely depends on whether customers want a bundled operator rather than a point solution.

Regulation is one of the clearer public forces shaping this market. Polaris Rx explicitly markets correctional-pharmacy programs around Section 1115 waiver implementation and pre-release healthcare coverage, placing part of its demand story in a policy-driven care transition market rather than ordinary retail pharmacy economics [Polaris Rx]. The company’s emphasis on HIPAA-compliant messaging and file sharing through PolarisDirect also points to a market where secure coordination is not optional overhead but part of the product requirement, especially across institutional and specialty use cases [PolarisDirect, Retrieved 2026] [Microsoft AppSource, Retrieved 2026].

Public market signal What it suggests for market scope Source
Polaris Rx says it serves long-term, post-acute, correctional, PACE, and specialty pharmacy settings Demand spans several institutional and specialty care channels rather than a single pharmacy niche [Polaris Rx]
Polaris began dispensing and shipping FluMist Home from five pharmacy locations for the 2025-2026 season At-home and programmatic distribution can require multi-site pharmacy execution [Polaris Rx, April 2025]
Bristol Myers Squibb selected Polaris Rx to dispense ZENBEXUS Manufacturer-directed specialty dispensing is part of the relevant adjacent market [Business Wire, November 2026]
Polaris markets Section 1115 waiver support in correctional pharmacy Medicaid and justice-health policy changes may expand operational demand in re-entry care [Polaris Rx]

The table does not size the market in dollars, but it does show where demand is coming from: institutional complexity, specialty launches, and policy-linked care transitions. For an investor, that points to a market defined more by workflow depth and regulatory fit than by raw script counts.

Unconfirmed -- This section relies primarily on company materials for market framing, with one independent corroborating announcement from Business Wire and no cited third-party market-sizing report in the available record.

Who Else Is Fighting for This

Market structure

MIXED Polaris Rx appears to compete less as a point-solution software vendor and more as an operating platform that sits between institutional care settings, drug manufacturers, and regulated dispensing workflows, which makes its nearest alternatives a mix of pharmacy-service incumbents, in-house provider operations, and partner-led distribution networks rather than a single clean peer set [Polaris Rx, April 2025] [Polaris Rx] [Business Wire, November 2026].

The public record here is thin on named direct competitors, and that matters for interpretation. Polaris itself presents a cross-setting footprint across long-term care, post-acute, correctional, PACE, infusion, and specialty pharmacy services [Polaris Rx] [Polaris Rx About Us], while its product surface includes customer workflow software through PolarisConnect and secure communications through PolarisDirect [Polaris Rx] [Microsoft AppSource]. That suggests competition happens segment by segment: in long-term care and post-acute, against established dispensing and fulfillment operators; in specialty and infusion, against accredited specialty pharmacies and manufacturer-selected dispensing networks; in correctional care, against regional pharmacy contractors and internal public-sector arrangements; and in workflow software, against portals and messaging layers bundled into broader pharmacy-service contracts rather than sold standalone [Polaris Rx] [Polaris Rx, Unknown].

The clearest public edge today is regulatory and operational adjacency, not software exclusivity. Polaris has publicly tied itself to manufacturer programs with AstraZeneca's FluMist Home distribution for the 2025-2026 season and Bristol Myers Squibb's ZENBEXUS dispensing role in November 2026, both of which indicate that large pharma counterparties were willing to place Polaris inside high-compliance distribution pathways [Polaris Rx, April 2025] [Business Wire, November 2026]. That edge could be durable if those relationships compound into repeat manufacturer trust across specialty launches and institution-facing programs, but it is also perishable because the underlying differentiation appears to rest on execution, network coverage, and compliance credibility rather than a public technology moat that would be difficult for larger incumbents to replicate [Polaris Rx] [PolarisDirect, Retrieved 2026].

Exposure is easiest to see in the same places where Polaris is trying to expand. The FluMist Home rollout explicitly relied on Asembia as HUB-services partner and ASPN Pharmacies for the technology platform and backend services, which implies Polaris does not own every layer of the patient-access and orchestration stack in manufacturer programs [Polaris Rx, April 2025]. That dependence is not unusual, but it limits control over channel economics and customer data relative to vertically integrated specialty operators. The software layer also looks supporting rather than category-defining on the evidence available: PolarisConnect requires login access for customers, and PolarisDirect offers HIPAA-compliant messaging and file sharing, but the public materials do not show that these tools are broad market products with independent adoption outside Polaris's pharmacy relationships [PolarisConnect, Retrieved 2026] [PolarisDirect, Retrieved 2026] [Microsoft AppSource, Retrieved 2026].

The most plausible 18-month scenario is that competitive outcomes diverge by channel rather than by company-wide dominance. A likely winner if manufacturer-sponsored specialty and home-administration programs keep growing is Asembia, because its named role as hub-services partner places it close to the referral and access workflow that can shape which dispensing partners benefit as new programs launch [Polaris Rx, April 2025]. A likely loser if branded drug distribution becomes more concentrated in a few tightly integrated networks is the in-house pharmacy model at smaller care operators, because those providers would struggle to match the compliance, logistics, and manufacturer contracting required for programs like FluMist Home or ZENBEXUS based on the operating complexity evident in Polaris's public partnerships [Polaris Rx, April 2025] [Business Wire, November 2026]. For Polaris itself, the competitive question is less whether it can out-software the field than whether it can convert these manufacturer and institutional footholds into a repeatable network position before larger incumbents compress the gap.

Opportunity

PUBLIC

The prize here is not another regional pharmacy operator, but a credible shot at becoming the operating layer that large drugmakers and institutional care settings rely on when a therapy or care model is too operationally difficult for generalist channels to handle [Polaris Rx, April 2025] [Business Wire, November 2026].

That upside starts with where Polaris Rx already appears to sit in the value chain. Public materials show a company that combines dispensing with clinical, logistics, regulatory, and technology services for complex-care populations, spanning long-term care, post-acute, correctional, PACE, and specialty workflows [Polaris Rx] [Polaris Rx About Us]. That is a wider operating surface than a stand-alone software vendor or a single-site pharmacy. The more important signal is customer type: AstraZeneca selected Polaris as exclusive U.S. distributor for FluMist Home for the 2025 to 2026 flu season, with dispensing and shipping launched from five pharmacy locations, and Bristol Myers Squibb selected Polaris to dispense ZENBEXUS for multiple myeloma [Polaris Rx, April 2025] [Business Wire, November 2026]. Those are not proof of category leadership, but they do indicate that at least two large pharmaceutical companies were willing to place Polaris inside commercially sensitive distribution and patient-access workflows.

The opportunity, in plain terms, is to become the default specialty and institutional pharmacy infrastructure partner for therapies and care programs that need more than dispensing. The public evidence supports that as reachable, not merely aspirational, because the company is already presenting a combined operating stack: physical pharmacy footprint, regulated fulfillment, secure communications through PolarisDirect, and workflow visibility through PolarisConnect [Polaris Rx] [Polaris Rx, April 2025] [Microsoft AppSource]. If that stack keeps winning narrow, high-friction programs first, it can expand account by account into a harder-to-replace platform role.

Scenario What happens Catalyst Why it's plausible
Pharma launch partner Polaris becomes a repeat launch and distribution partner for specialty drugs that need controlled dispensing, patient support, and regulated fulfillment The Bristol Myers Squibb ZENBEXUS selection creates a reference case with a top-tier pharma company [Business Wire, November 2026] Polaris has already been selected for named pharma programs by Bristol Myers Squibb and AstraZeneca, which suggests it can meet manufacturer requirements in at least some high-compliance launches [Business Wire, November 2026] [Polaris Rx, April 2025]
Institutional care operating system PolarisConnect and PolarisDirect evolve from customer tools into embedded workflow infrastructure across long-term care, post-acute, correctional, and PACE customers Existing portal and secure messaging products gain broader adoption inside current service relationships [Polaris Rx] [Microsoft AppSource] The company already serves multiple care settings and offers software tied to ordering, tracking, reporting, alerts, and HIPAA-compliant communication, which is the kind of utility layer that can deepen switching costs over time [Polaris Rx] [PolarisConnect] [PolarisDirect, Retrieved 2026]
Correctional and waiver access specialist Polaris becomes a preferred pharmacy partner for correctional health programs tied to Medicaid Section 1115 waiver implementation and pre-release coverage Expansion of waiver-driven pre-release healthcare coverage increases demand for pharmacies that can handle continuity-of-care logistics [Polaris Rx] Polaris already markets a correctional-pharmacy offering built around Section 1115 waiver implementation, which indicates management sees a real and growing administrative need in that channel [Polaris Rx]

The compounding mechanism is straightforward even if the public evidence is still thin. Each manufacturer relationship or institutional deployment can add volume to the same underlying system of pharmacy locations, compliance processes, customer portal workflows, and secure communications infrastructure [Polaris Rx] [PolarisConnect] [Microsoft AppSource]. In this model, one win does not just add script volume. It can also create a reference account, improve credibility with regulators and pharmaceutical partners, and make the technology layer more central to daily operations for providers and care facilities.

There is also an early form of distribution lock-in visible in the FluMist Home program. Polaris was named exclusive U.S. distributor for that service, while Asembia and ASPN Pharmacies supported adjacent hub and technology functions, implying Polaris can sit inside a broader partner network rather than trying to own every layer itself [Polaris Rx, April 2025]. If that pattern repeats, the company does not need to be the only vendor in the chain. It only needs to be the regulated pharmacy and workflow node that other participants route through.

The size of the win is harder to pin down because no public market-sizing data or direct public-peer framework was supplied in the source set. The most defensible upside statement is therefore strategic rather than fully modeled: if Polaris were to become a repeat national partner for complex specialty launches and institutional medication workflows, it could plausibly grow from a private operator into a scarce infrastructure asset in healthcare services and pharmacy distribution, with value driven by contracted manufacturer relationships, recurring facility workflows, and software-enabled retention (scenario, not a forecast) [Business Wire, November 2026] [Polaris Rx, April 2025]. What matters for the upside case is that the company already shows signs of participating in nationally relevant programs, rather than merely describing an ambition to do so.

Unconfirmed -- This section relies materially on company statements and one named-publisher announcement, with limited independent corroboration for scale, product adoption, and market size.

Sources

From the public record

  1. [Polaris Rx, April 2025] Polaris Pharmacy Services Named Exclusive U.S. Distributor of AstraZeneca’s FluMist® Home Service, The World’s First At-Home Nasal Spray Flu Vaccine | https://polarisrx.com/polaris-pharmacy-services-named-exclusive-u-s-distributor-of-astrazenecas-flumist-home-service-the-worlds-first-at-home-nasal-spray-flu-vaccine/

  2. [Business Wire, November 2026] Polaris Rx Selected by Bristol Myers Squibb to Dispense ZENBEXUS™ (iberdomide), the First FDA-Approved CELMoD Therapy for Multiple Myeloma | https://www.businesswire.com/news/home/20261104994395/en/Polaris-Rx-Selected-by-Bristol-Myers-Squibb-to-Dispense-ZENBEXUS-iberdomide-the-First-FDA-Approved-CELMoD-Therapy-for-Multiple-Myeloma

  3. [Polaris Rx] About Us | https://polarisrx.com/about-us/

  4. [Microsoft AppSource] PolarisDirect | https://appsource.microsoft.com/

  5. [LinkedIn, Retrieved 2026] Christopher Vinosky, Polaris Pharmacy Services | LinkedIn | https://www.linkedin.com/in/christophervinosky/

  6. [RocketReach, Retrieved 2026] Steve Baker Email & Phone Number | Polaris Pharmacy Services Chief Operating Officer Contact Information | https://rocketreach.co/steve-baker-email_18382373

  7. [Craft.co] Polaris Pharmacy Services Company Profile, Office Locations, Competitors, Revenue, Financials, Employees, Key People, Subsidiaries | Craft.co | https://craft.co/polaris-pharmacy-services

  8. [AOL, September 2026] FluMist Home service available for 2026-2027 flu season | https://www.aol.com/

  9. [PolarisConnect] PolarisConnect | https://polarisrx.com/polarisconnect/

  10. [PolarisDirect, Retrieved 2026] PolarisDirect | https://polarisrx.com/polarisprescribe/

  11. [Polaris Rx About Us] About Us | https://polarisrx.com/about-us/

Articles about Polaris Rx

View on Startuply.vc